Jeena Sikho Lifecare Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Jeena Sikho Lifecare Ltd filed with BSE on 08 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jeena Sikho Lifecare reported FY26 revenue from operations of INR801 crores, up 71% year-on-year, with EBITDA of INR349 crores at a 44% margin and PAT of INR222 crores, up 177%. Management attributed Q4 profit softness to one-time items including labour code provisioning, ESOP costs, a leasehold accounting review under new auditor Grant Thornton, and an ECL provision totaling approximately INR21 crores. Management also described plans to expand operational beds from about 2,300 toward 3,000 in the coming months and outlined a target of 7,000 to 10,000 beds over three to five years.
Numbers mentioned
Revenue from operations: INR801 crores (FY26)
p. 4
“On the financial side, revenue from operations in FY26 was INR801 crores, a 71% year-on-year growth.”
Manish Grover, page 4 of the filed PDF · View the filing
EBITDA margin: 44% (FY26)
p. 4
“EBITDA margin in FY26 reached 44%, up from 30% in FY25, an improvement of 1,360 basis points in a single year.”
Manish Grover, page 4 of the filed PDF · View the filing
EBITDA: INR349 crores (FY26)
p. 4
“FY26 EBITDA was INR349 crores, up 149% year-on-year.”
Manish Grover, page 4 of the filed PDF · View the filing
PAT: INR222 crores (FY26)
p. 4
“FY26 PAT was INR222 crores, up 177% year-on-year, with a 28% PAT margin.”
Manish Grover, page 4 of the filed PDF · View the filing
Revenue from operations: INR216 crores (Q4 FY26)
p. 5
“For the quarter, our revenue from operations stood at INR216 crores, up by 55% year-to-year.”
Nanak Chand, page 5 of the filed PDF · View the filing
EBITDA: INR78 crores (Q4 FY26)
p. 5
“Our EBITDA came in at INR78 crores, recording 70% year-on-year growth with a margin of 36%.”
Nanak Chand, page 5 of the filed PDF · View the filing
Profit after tax: INR45 crores (Q4 FY26)
p. 5
“Profit after tax stood at INR45 crores, reflecting a 79% year-on-year growth.”
Nanak Chand, page 5 of the filed PDF · View the filing
Basic EPS: INR3.65 (Q4 FY26)
p. 5
“Our basic EPS for the quarter is INR 3.65.”
Nanak Chand, page 5 of the filed PDF · View the filing
Gross margin: 89% (FY26)
p. 6
“With a gross margin of 89%, our EBITDA came in at INR 349 crores, growing by 149%, while the EBITDA margin grew by a whopping 1,360 basis points to 44%.”
Nanak Chand, page 6 of the filed PDF · View the filing
PAT margin: 28% (FY26)
p. 6
“Our PAT also registered a robust growth of 177% to INR222 crores, with the PAT margin registering a robust growth of 1,062 bps to 28%.”
Nanak Chand, page 6 of the filed PDF · View the filing
Product business revenue contribution: INR416 crores, 52% of total revenue (FY26)
p. 4
“In FY26, this vertical contributed INR416 crores, which is 52% of the total revenue.”
Manish Grover, page 4 of the filed PDF · View the filing
IPD patient volume growth: 65% to 40,450 (FY26)
p. 4
“For the full year FY26, IPD patient volume increased by 65% to 40,450.”
Manish Grover, page 4 of the filed PDF · View the filing
OPD patient volume growth: 69% to over 6,00,000 (FY26 vs FY25)
p. 4
“OPD patient volume increased by 69% from FY25 to reach over 6,00,000.”
Manish Grover, page 4 of the filed PDF · View the filing
Operational beds: 2,300 (current)
p. 5
“Currently, we have about 2,300 operational beds, which we will increase to 3,000 operational beds in the next 3 to 4 months, with 445 more in active deployment.”
Manish Grover, page 5 of the filed PDF · View the filing
Advertising spend: INR66 crores (FY26)
p. 11
“And this year, we collected INR800 crores by spending only INR66 crores on advertising.”
Manish Grover, page 11 of the filed PDF · View the filing
Health insurance contribution to sales: 26% (current)
p. 17
“Today, my health insurance contribution has reached 26% in total sales.”
Manish Grover, page 17 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Operational beds — 3,000 to 3,500 beds · before March 31st (next year)
stated firmly by Manish Grover
p. 19
“Yes. This year I will reach 3,000 to 3,500 beds before March 31st.”
Manish Grover, page 19 of the filed PDF · View the filing
Operational beds (long-term) — 7,000 to 10,000 beds · 3 to 5 years
stated as an aspiration by Manish Grover
p. 5
“Our target for 3 to 5 years is 7,000 to 10,000 beds.”
Manish Grover, page 5 of the filed PDF · View the filing
PAT — 4x to 5x from current level · next 4 years
stated as an aspiration by Manish Grover
p. 5
“The target for the next 4 years is to increase PAT by about 4x to 5x from here.”
Manish Grover, page 5 of the filed PDF · View the filing
PAT — minimum INR300 crores · FY27
stated conditionally by Manish Grover
p. 20
“Sir, minimum INR300 crores PAT is my minimum that I have to achieve. How much more it will go, I don't know.”
Manish Grover, page 20 of the filed PDF · View the filing
Revenue — INR3000 crores · 3 to 5 years
stated as an aspiration by Manish Grover
p. 7
“We see INR3000 crores in sales in the next 3 to 5 years, so why would we focus on INR2 crores to INR4 crores?”
Manish Grover, page 7 of the filed PDF · View the filing
Product mix (services vs products) — approximately 50-50 · at INR3000 crores revenue
stated firmly by Manish Grover
p. 14
“Approximately everything will be 50-50. If you listen to my last four or five concalls, I have said that our mix will remain 50-50.”
Manish Grover, page 14 of the filed PDF · View the filing
Bed expansion capability — 2,000 beds · within a year, once payment portal is fixed
stated conditionally by Manish Grover
p. 9
“As soon as any news comes from the Government of India and their payment portal is fixed, I have the power to immediately increase 2,000 beds within a year.”
Manish Grover, page 9 of the filed PDF · View the filing
Non-operational beds — all made operational · next 3 to 5 months
stated firmly by Manish Grover
p. 9
“But now I will increase them in the next 3 to 5 months; I will make all nonoperational beds operational.”
Manish Grover, page 9 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the decline to advance-booked preventive customers delaying visits due to panic from the Iran-America war situation and rumors about cylinder shortages.
Answered by Manish Grover
Asked by Akshay: Why did OPD, IPD and daycare volumes slightly decline in Q4?
p. 6
“Sir, it happened because of Trump sir, because panic spread across the whole country.”
Manish Grover, page 6 of the filed PDF · View the filing
Management confirmed the understanding and detailed the components of the one-time items including bonus, lease provisioning, health card impact, and gratuity.
Answered by Manish Grover
Asked by Ankur: If the INR21 crores extraordinary items are added back, would EBITDA margin be 46%?
p. 8
“You are absolutely right. Actually, what happened is that our labour laws changed, so the impact of that came in.”
Manish Grover, page 8 of the filed PDF · View the filing
CFO clarified that employee benefit and ECL provisions were one-time, while leasehold impact would gradually reduce each quarter going forward, with about INR19 crores being one-time.
Answered by Nanak Chand
Asked by Chirag Shah: How much of the INR21 crores one-off is recurring versus one-time?
p. 12
“the employee benefit of INR7 crores and the ECL provision of INR5 crores are one-time.”
Nanak Chand, page 12 of the filed PDF · View the filing
CFO stated INR19-20 crores was one-time and the remainder recurring, with additional depreciation of about INR5 crores also impacting the quarter.
Answered by Nanak Chand
Asked by Deepak Poddar: What is the exact bifurcation of one-time versus recurring within the INR21 crores?
p. 13
“INR19 crores to INR20 crores is a one-time impact, and the remaining will be recurring.”
Nanak Chand, page 13 of the filed PDF · View the filing
Management said the mix would stay roughly 50-50, citing a shift from government to private and retail sales.
Answered by Manish Grover
Asked by Naveen Baid: How will the services versus products revenue mix evolve as revenue scales to INR3000 crores?
p. 14
“Last year we did government sales of INR118 crores. This whole year, I did INR36 crores.”
Manish Grover, page 14 of the filed PDF · View the filing
Management described rising health insurance contribution and ongoing negotiations with insurers like HDFC ERGO to increase bed utilization and ticket size.
Answered by Manish Grover
Asked by Hitesh Jain: How will unit economics on a per-bed basis change as revenue scales to INR3,000 crores?
p. 17
“Today, my health insurance contribution has reached 26% in total sales.”
Manish Grover, page 17 of the filed PDF · View the filing
Management said all non-operational beds would be made operational within 3-5 months and targeted 3,000-3,500 beds before next fiscal year-end.
Answered by Manish Grover
Asked by Abhishek: How many operational beds are targeted by end of next year?
p. 19
“Yes. This year I will reach 3,000 to 3,500 beds before March 31st.”
Manish Grover, page 19 of the filed PDF · View the filing
Management gave a minimum PAT figure without committing to an upper bound.
Answered by Manish Grover
Asked by Praveen Kumar: What is the revenue/PAT guidance for FY27?
p. 20
“Sir, minimum INR300 crores PAT is my minimum that I have to achieve. How much more it will go, I don't know.”
Manish Grover, page 20 of the filed PDF · View the filing
Management provided repeat business percentages for the prior quarter across the hospital and product segments.
Answered by Manish Grover
Asked by Priyanshu Jain: What is the repeat purchase rate for hospital and product customers?
p. 22
“In the last quarter's data, in our hospital business, if I take the admitted business, there was a 26% repeat business.”
Manish Grover, page 22 of the filed PDF · View the filing
Management said the pace depends on shifting consumer mindset toward preventive care and cited media appearances as part of building demand before filling beds.
Answered by Manish Grover
Asked by Priyam: Will the bed expansion to 7,000-10,000 beds be evenly spread or lumpy over the next five years?
p. 23
“So, it will take me three or four months for that narrative to change. As soon as the narrative changes, sir, filling beds won't be difficult at all, because currently, the mind of India is curative.”
Manish Grover, page 23 of the filed PDF · View the filing
Risks flagged
Geopolitical events (Iran-America tensions, India-Pakistan war situation) causing customer booking delays
p. 12
“We suffered two shocks last year. First, the India-Pakistan war situation happened around our second quarter. Then this America and Iran shock happened around the fourth quarter.”
Manish Grover, page 12 of the filed PDF · View the filing
Delayed and stuck government payments affecting government business
p. 14
“It's not that the government is refusing to do business. I could have done INR80 crores, but the credit gets stuck, then provisions have to be taken, government money comes late.”
Manish Grover, page 14 of the filed PDF · View the filing
One-time accounting and provisioning impacts from new auditor and labour code changes affecting quarterly earnings
p. 6
“there is a short-term impact of one-time nonrecurring items, largely on account of higher provisioning related to the new labour code, ESOP provisioning, and certain performance-linked bonuses of approximately INR7 crores.”
Nanak Chand, page 6 of the filed PDF · View the filing
Government scrutiny and blacklisting risk for hospitals dependent on government billing
p. 15
“Because the government is catching so many scams in hospital billing that those hospitals then get blacklisted.”
Manish Grover, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.